JPH0324480B2 - - Google Patents

Info

Publication number
JPH0324480B2
JPH0324480B2 JP59248259A JP24825984A JPH0324480B2 JP H0324480 B2 JPH0324480 B2 JP H0324480B2 JP 59248259 A JP59248259 A JP 59248259A JP 24825984 A JP24825984 A JP 24825984A JP H0324480 B2 JPH0324480 B2 JP H0324480B2
Authority
JP
Japan
Prior art keywords
digitalis
producing
antibody
fab
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59248259A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60132922A (ja
Inventor
Batsutsu Hansuugeoruku
Yungufuaa Heruberuto
Rentsu Herumuuto
Reedaa Aruberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of JPS60132922A publication Critical patent/JPS60132922A/ja
Publication of JPH0324480B2 publication Critical patent/JPH0324480B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP59248259A 1983-11-26 1984-11-26 ジギタリス抗体の製造法 Granted JPS60132922A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
DE3342870.0 1983-11-26

Publications (2)

Publication Number Publication Date
JPS60132922A JPS60132922A (ja) 1985-07-16
JPH0324480B2 true JPH0324480B2 (OSRAM) 1991-04-03

Family

ID=6215371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59248259A Granted JPS60132922A (ja) 1983-11-26 1984-11-26 ジギタリス抗体の製造法

Country Status (8)

Country Link
US (1) US4742159A (OSRAM)
EP (1) EP0143413B1 (OSRAM)
JP (1) JPS60132922A (OSRAM)
AT (1) ATE64141T1 (OSRAM)
CA (1) CA1242393A (OSRAM)
DE (2) DE3342870A1 (OSRAM)
ES (1) ES8600770A1 (OSRAM)
SU (1) SU1455999A3 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
JP4837221B2 (ja) * 2000-05-25 2011-12-14 株式会社カネカ 強心配糖体の吸着材、吸着除去方法および吸着器
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6802966B2 (en) * 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US6987079B2 (en) * 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN106659909B (zh) 2013-08-21 2022-01-11 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
ES2883297T3 (es) 2016-03-29 2021-12-07 Stcube Inc Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
AU2018277838C1 (en) 2017-05-31 2025-08-07 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
US20200290978A1 (en) 2017-09-26 2020-09-17 The Regents Of The University Of California Compositions and methods for treating cancer
EP3802616A4 (en) 2018-06-04 2022-03-30 University of Maryland, Baltimore PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Also Published As

Publication number Publication date
SU1455999A3 (ru) 1989-01-30
ES537909A0 (es) 1985-11-01
EP0143413A2 (de) 1985-06-05
ATE64141T1 (de) 1991-06-15
US4742159A (en) 1988-05-03
EP0143413B1 (de) 1991-06-05
DE3484673D1 (de) 1991-07-11
EP0143413A3 (en) 1988-07-20
ES8600770A1 (es) 1985-11-01
JPS60132922A (ja) 1985-07-16
CA1242393A (en) 1988-09-27
DE3342870A1 (de) 1985-06-05

Similar Documents

Publication Publication Date Title
JPH0324480B2 (OSRAM)
US4361509A (en) Ultrapurification of factor VIII using monoclonal antibodies
KR102079487B1 (ko) Ｉｇａ를 농축시키는 방법
JPH08511015A (ja) 治療用抗体断片
JPH06107561A (ja) 静脈内相容性免疫グロブリン− ｇ− 製剤の製造方法
US20030190732A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
US4746731A (en) Isolated tissue protein PP18
JPH09506256A (ja) メンブレンクロマトグラフィーによるビタミンｋ依存性蛋白の精製
US4232004A (en) Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
JPH0132839B2 (OSRAM)
Aalberse et al. The purification of human polyclonal IgE by immunosorption
RU2148411C1 (ru) Способ получения с помощью хроматографических методов вирусно-инактивированной фракции, содержащей фактор viii
US4594328A (en) Tissue protein PP21, a process for obtaining it and its use
US20090281282A1 (en) Method for the isolation of haptoglobin
RU2325171C1 (ru) Способ выделения и очистки трофобластического бета-1-гликопротеина
KR100245542B1 (ko) 응고 인자 xiii 또는 xiiia의 정제방법 및 인자 xiiia에 대한 모노클로날 항체
Biewenga et al. Binding of human IgA myeloma proteins to protein A. Evidence for different binding mechanisms
JP4777599B2 (ja) ヒト抗胸腺細胞免疫グロブリンの製造方法
JP2001509170A (ja) フォンビルブラント因子含有出発物質からのフォンビルブラント因子のクロマトグラフィー精製法または分画法
EP0539584B1 (en) Reagent for diagnosing mycoplasma pneumoniae
JP2519561B2 (ja) 酸性糖タンパク質
JPS62258399A (ja) Ｃ−反応性蛋白質の精製方法
JPH07121876B2 (ja) 静注用免疫グロブリンの製法
CN101316933A (zh) 浓缩、纯化和除去朊病毒蛋白质的方法
JP2006026607A (ja) アフィニティークロマトグラフィー用吸着体

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term